Latest news with #fiscal2026
Globe and Mail
22-07-2025
- Business
- Globe and Mail
STERIS to Host a Conference Call for Fiscal 2026 First Quarter Results on August 7, 2025
DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ('STERIS' or the 'Company') announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 6, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 7, 2025, either at or via phone. To access the replay of the call, please use the access code 2889488 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally. About STERIS STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit Company Contact: Julie Winter, Vice President, Investor Relations and Corporate Communications Julie_Winter@ +1.440.392.7245 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded 'forward-looking statements' under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as 'may,' 'will,' 'expects,' 'believes,' 'anticipates,' 'plans,' 'estimates,' 'projects,' 'targets,' 'forecasts,' 'outlook,' 'impact,' 'potential,' 'confidence,' 'improve,' 'optimistic,' 'deliver,' 'orders,' 'backlog,' 'comfortable,' 'trend,' and 'seeks,' or the negative of such terms or other variations on such terms or comparable terminology. Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS's recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS's ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS's performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS's businesses, industry or initiatives may adversely impact STERIS's performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS's indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS's Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.
Yahoo
20-07-2025
- Business
- Yahoo
Down 16%, Should You Buy the Dip on Arm Holdings?
Key Points Arm stock is trading 16% off all-time highs hit last summer. Arm's valuation remains lofty when compared to other stocks in the technology sector. Arm has what it takes to generate enough growth to justify its premium valuation. 10 stocks we like better than Arm Holdings › Arm Holdings (NASDAQ: ARM) stock has underperformed the technology sector of late. It is trading down about 16% from its all-time high set in mid-2024, while the tech-focused Nasdaq Composite index is trading at or near all-time highs despite enduring a tough time earlier this year. However, a closer look at Arm's stock price chart tells us that it is regaining its mojo once again. Shares of the company have jumped 56% in the past three months, outpacing the Nasdaq Composite's 28% gains. Importantly, the stock could get a solid boost when it releases its fiscal 2026 first-quarter results after the market closes on July 30. Now, Arm stock is trading at a more attractive valuation than it was a year ago, thanks to the 16% dip. That's why now may be a good time to start accumulating Arm, as it seems primed for more upside in the second half of 2025 and beyond. Arm's robust growth has made the stock relatively cheaper Even though Arm's stock price has headed south in the past year, the company's earnings have been growing at an impressive pace in the past 18 months. This is evident from the following chart. This is why Arm can now be bought at a relatively cheaper valuation. It is trading at 193 times earnings right now, which is almost a third of its price-to-earnings ratio at the end of June 2024. Additionally, its forward earnings multiple of 79 tells us that analysts are expecting a nice jump in the company's earnings going forward. Of course, Arm's valuation remains at lofty levels when we consider that the U.S. technology sector has an average earnings multiple of 51. But the company is capable of justifying its valuation by clocking healthy levels of earnings growth, thanks to the fast-growing adoption of its latest chip architecture that's contributing positively toward its margins. The company is capable of delivering terrific bottom-line growth Arm licenses its chip architecture and intellectual properties (IP) to semiconductor companies that use them to design chips. The company gets its revenue from licensing agreements that it enters into with customers, along with royalties that it gets from each chip that is manufactured using its design. The good part is that the demand for Arm's IP and chip architecture has improved following the advent of artificial intelligence (AI). That's not surprising, as processors designed using Arm's architecture are said to be better at tackling advanced AI workloads while being power-efficient at the same time, as per third-party analysis. This explains why there has been a whopping 14x jump in the number of customers using Arm-based chips in data centers in just four years. Cloud computing giants such as Alphabet's Google, Amazon, and Microsoft are developing custom AI processors for their data centers using Arm's IP. The company has also seen a significant jump of 12x in the number of start-ups using its architecture for designing chips in the past four years. Arm's terrific progress in the data center market can also be attributed to a big spike in the number of applications that processors developed using its architecture can run. The company points out that the number of applications that can run on Arm-based chips has doubled since 2021, on the back of a 1.5x jump in the number of developers making those applications. As such, it's easy to see why Arm is confident of increasing its share of data center central processing units (CPUs) to 50% by the end of 2025, which would be more than triple last year's reading. The British company also expects to corner 50% of the PC CPU market by 2029, which would be a sixfold jump compared to last year. Even better, the royalties that Arm commands for its latest Armv9 architecture are reportedly double those of the previous generation. This is the reason why there has been a nice jump in the company's margin profile in the past 18 months. Arm is capable of clocking healthy earnings growth levels going forward, and that's precisely what analysts are expecting from the company. However, don't be surprised to see Arm's earnings growing at a faster pace than analysts' expectations, thanks to a combination of market share gains and the higher royalty rates for its AI-focused chip designs. Investors looking to add a growth stock to their portfolios can consider buying Arm, as the argument above indicates that it is set to soar higher on the back of an improvement in its earnings power. Should you invest $1,000 in Arm Holdings right now? Before you buy stock in Arm Holdings, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Down 16%, Should You Buy the Dip on Arm Holdings? was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
E&E News
15-07-2025
- Politics
- E&E News
Forest Service research survives in House spending bill
House appropriators Monday turned away a Trump administration effort to slash the Forest Service's research budget, proposing to hold spending steady at about $300 million in fiscal 2026. The proposal by the Republican-led House Appropriations Committee is part of an $8.5 billion annual spending plan for the Forest Service that largely ignores the administration's most far-reaching proposals. Total spending for the fiscal year beginning Oct. 1 would be $16.8 million less than this year's level. Spending not directly tied to fire suppression would total $3.6 billion, or about $107 million less than this year. The measure is scheduled for a subcommittee markup Tuesday. Advertisement The research budget would total $302 million, of which $34 million would be reserved for forest inventory and analysis — the data-collecting operation that the administration hadn't looked to scale back.
Yahoo
10-07-2025
- Business
- Yahoo
Dr. Martens Says Its Fall Order Books Are ‘Healthy' as New Fiscal Year Starts In-Line With Expectations
Dr. Martens is maintaining its outlook for fiscal 2026 as the company said on Thursday that the start of this new financial year is currently 'in-line with expectations.' In a statement issued ahead of the company's annual general meeting, Dr. Martens noted that it has continued to see positive trading in its Americas direct-to-consumer channel, driven by full price sales, particularly in retail. More from WWD UK Retailer Footasylum Touts 'Standout Performance' in Fiscal 2025 Nike CEO Says Q4 Results 'Are Not Where We Want Them to Be' Amid Turnaround Push Hit by Tariffs, U.S. Furniture-maker MillerKnoll Swings to Net Loss in Fiscal 2025 As for the EMEA region, the company noted that its DTC business remains more variable, with the UK business in particular continuing to experience a challenging trading backdrop. And in APAC, business continues to show good growth, with a particularly strong performance in South Korea driven by Dr. Martens shoes category, the company noted. Looking forward, Dr. Martens noted that its autumn/winter order books globally are 'healthy,' with the EMEA order book up year-on-year, and the Americas order book 'broadly in line' year-on-year. Looking ahead, the company said it is focused on embedding its new consumer-first 'Levers for Growth' strategy, which Dr. Martens outlined in June and builds on the work undertaken in fiscal 2025 to stabilize the business. 'The strategy capitalizes on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us,' the company said in a statement. 'It is centered on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model.' This news comes one month after chief executive officer Ije Nwokorie, who took the helm this year, told analysts that the company's 'single focus' in fiscal 2025 was to bring stability back to Dr. Martens. 'We have achieved this by returning our direct-to-consumer channel in the Americas back to growth, resetting our marketing approach to focus relentlessly on our products, delivering cost savings, and significantly strengthening our balance sheet,' Nwokorie said in June. In fiscal 2025, the U.K.-based footwear company reported that net revenue fell 10 percent to 787.6 million pounds from 877.1 million pounds in fiscal 2024. Dr. Martens noted that the results were in line with guidance, however, and came up against a challenging macroeconomic and consumer backdrop in several of its core markets. Net debt for the year was 249.5 million pounds, down from 359.8 million pounds in fiscal 2024. Net profit stood at 4.5 million pounds in the year to the end of March, down from 69.2 million pounds the year prior. Further details on the company's early progress will be shared in its first half results in November. Best of WWD All the Retailers That Nike Left and Then Went Back Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS] Julia Fox's Sleekest and Boldest Shoe Looks Over the Years [Photos]
Reuters
07-07-2025
- Business
- Reuters
India's Titan says first-quarter domestic sales up 19%
July 7 (Reuters) - Jewellery and watchmaker Titan Company ( opens new tab said in a business update on Monday that its domestic business sales grew by 19% in the first quarter of fiscal 2026.
